Table 2.
Detection of prostate cancer by screening FDG-PET and/or by each of the combined screening tests.
| Screening test | Number of cases | Performance of each test | Performance if combined with FDG-PET | |||||
|---|---|---|---|---|---|---|---|---|
| Total | Positive* | Proven cancer* | Unfound cancer* | Relative sensitivity** (%) | PPV** (%) | Relative sensitivity** (%) | PPV** (%) | |
| FDG-PET*** | 504 | 186 | 61 | 104 | 37.0 | 32.8 | - | - |
| Dedicated PET scanner | 148 | 31 | 10 | 39 | 20.4 | 32.3 | - | - |
| PET/CT scanner | 356 | 157 | 51 | 65 | 44.0 | 32.5 | - | - |
| Pelvic MRI | 227 | 152 | 55 | 29 | 66.5 | 36.2 | 67.9 | 33.5 |
| Serum PSA | 466 | 387 | 142 | 12 | 92.2 | 36.7 | 96.1 | 34.0 |
*
Out of the cases who underwent the test.
**
Analyzed on the subset of cases who underwent the test.
***
FDG-PET includes dedicated PET and PET/CT. PPV: positive predictive value, PSA: prostate specific antigen